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INTRODUCTION

27
Parkinson's disease 28 [58, 59] [66, 67] . COMT is a ubiquitously expressed 105 catabolic enzyme with soluble and membrane bound 106 isoforms [68] that can methylate (inactivate) cate-107 cholamines as well as their hydroxylated derivatives 108 and catechol structured drugs such as L-dopa [69, 70] . 109 Specifically, COMT catalyzes the magnesium depen-110 dent transfer of the methyl groups from the coenzyme 111 S-adenosyl-l-methionine to the m-hydroxyl group of 112 catechol compounds [71, 72] , such as the conversion 113 of L-dopa to 3-O-methyl dopa (3-OMD) [73] [74] [75] . The 114 latter metabolite has no therapeutic value and a long 115 half-life (∼15 h) [76] as opposed to the 60-90 min-116 utes of L-dopa [77] . Its properties include a further 117 reduction of L-dopa's bioavailability in the brain by 118 competing for active transport across the blood-brain 119 barrier [78, 79] though the clinical significance of this 120 finding has been contended in the relevant literature 121 [80, 81] .
122
COMT inhibition
123
COMT inhibitors (COMTIs) were examined ini- (entacapone, tolcapone, opicapone) . PET scan studies and animal studies suggest that tolcapone may be able to also inhibit COMT in the CNS [64, 65] .
Moreover, entacapone is thought to be acting in L-dopa, whereas tolcapone has a longer 4 h half-144 life and higher bioavailability (∼65% vs 35%) [84, 145 88-91] . Therefore, it is recommended that tolcapone 146 is administered three times every day, whereas enta-147 capone is administered with every scheduled dose as 148 a separate medication [82, 92, 93] It has a very high binding affinity and thus a pro-190 longed dissociation rate constant [109] . Indicatively, 191 in human erythrocytes, the half-life of opicapone
192
U n c o r r e c t e d A u t h o r P r o o f induced COMT inhibition is over 100 h [110] . In a 193 pilot study, Ferreira et al. (2015) (Fig. 2) .
260
RESULTS
261
Twelve RCTs with a total of 3701 participants were 262 included in this systematic review [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] Table 1 .
309
DISCUSSION
310
COMTIs have been shown to prolong the thera-311 peutic effect of L-dopa in different study designs, 312 but due to methodological differences their clini-313 cal benefit in PD patients is not well defined [102] .
314
The primary aim of this review was to compare is the reason why studies proceeded with the addi-435 tion of riboflavin in the placebo [112] . Lastly, even 436 though entacapone is a chelator [136] , there were no 437 increased cases of anaemia compared to placebo.
U n c o r r e c t e d A u t h o r P r o o f
438
Limitations and future studies 439 The length of the studies was short and therefore
440
it is difficult to have these findings extrapolated into 
449
In addition, all studies except for one [114] 
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